Pre-close Trading Statement & Notice of Results

20 August 2015

Quantum Pharma Plc

("Quantum" or the "Group")

Pre-close Trading Statement

and

Notice of Half Year Results

Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce its pre-close trading update for the half year ended 31 July 2015.

The Board is pleased to announce that Quantum has made good strategic progress across all areas of its business in the last six months. Trading for the Group remains in line with market expectations for the year to 31 January 2016.

As previously announced Quantum completed the acquisitions of the Lamda group of companies and NuPharm Group during this period. The Board is confident that these businesses will add value to the Group in the future.

Colonis, the specialist pharmaceutical product development business, continues to grow its pipeline and submissions to the relevant authorities and to progress its product launch programme:

· over 70 regulated products (licensed products and medical devices) are now in the pipeline with a number of other opportunities to increase the pipeline further during this financial year (May 2015: 60 regulated products).

· 16 products are in for assessment with the MHRA and other authorities for registration. That number is expected to be at least 28 by the end of this financial year. 

· two products have been launched in the market (one licensed product and one medical device). The second licensed product is manufactured and awaiting final release permission from the MHRA to enter the market. It is anticipated that this will be received by the end of September. 

· 11 regulated products are expected to have been launched by the end of the financial year. There are also a number of active opportunities for additional regulated products to be brought into the pipeline and launched this year.

The Board remains confident that licences will be achieved for all products submitted for assessment to the relevant regulators although, in respect of a small number of applications made earlier in the year, this is taking longer than expected.

Quantum will announce its half year results for the six months ended 31 July 2015 on Tuesday 20 October 2015.

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "The first six months of the financial year have been a busy period at Quantum Pharma.  We successfully completed the strategic acquisitions of Lamda and NuPharm and the integration of both these companies into the Group is ongoing. In addition, pleasingly, a number of the business units have had record half years.

Progress continues to be made on the Colonis pipeline, and we look forward to announcing a number of further regulated product launches during the second half of the year. As is sometimes the case, the regulatory process on certain products is taking slightly longer than anticipated, however we are confident of securing licences for all products in assessment with the MHRA and other regulators. We look forward to presenting our half year results in October." 

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. The Quantum Pharma Group operates through seven business units offering a portfolio of innovative and complementary products and services to providers in primary and secondary care.

Quantum Pharmaceutical manufactures and supplies specials and special obtains for the majority of large retail pharmacy chains in the UK, as well as large pharmaceutical wholesalers, hospitals and independent pharmacies. Specials are bespoke, non-licensed medicines which can be custom manufactured as a one-off or procured for individual patient needs where a clinician deems a patient requires a bespoke formulation for their treatment. The company can manufacture and supply bespoke medicines in as little as 15 hours and regularly services around 6,500 pharmacies across the UK with a choice of more than 22,000 specials or special obtains.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches. Serving the hospital market (both NHS and private) and homecare patients, its unique, six-day-a-week, next morning (by 10.30am) compounding service enables many hospitals to offer chemotherapy treatment five days a week, unencumbered by the delays of aseptic production.

UL Medicines sources and supplies unlicensed imported medicines and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas. The company offers approximately 500 imported medicines sourced from more than 24 countries, as well as a specialist over-labelling service that translates accompanying local language patient documentation into English.

Biodose® is the only medicines delivery system that accommodates both liquid and solid medication, supporting medicines administration and adherence for 50,000 patients with complex medication regimes, their carers and clinicians. Building on its success, Biodose Connect®, due for launch in early 2016, incorporates telemedicines technology to provide live, remote monitoring and management of patient adherence to prevent avoidable and costly hospital admissions.

Biodose Services® provides pre-prepared medication regimes to care homes and delivery of medication to the home. Biodose Services is the UK's largest provider of the Biodose system and operates from a 7,600ft purpose-designed specialist pharmacy in West Yorkshire. The company also offers a range of homecare services to the NHS, private clinics and pharmaceutical companies including the Stork Fertility Service®, premium homecare for patients receiving fertility treatment.

Colonis is a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated product status. Colonis launched its first licensed product, Aviticol in December 2014. Colonis has also launched one regulated product and a second licensed product is being manufactured ready for launch. The company is currently working on a significant pipeline of approximately 70 products (SKUs) across a growing number of therapeutic areas, 16 of which have been submitted for approval to the MHRA.

Lamda is a full service contract development specialist with customers in the UK, Ireland, Germany, France, Italy, Sweden, Greece and Cyprus. As well as providing in-house development for the Colonis pipeline, Lamda provides a fully outsourced research and development service for pharmaceutical companies looking to develop pharmaceutical forms or to license medicinal products.

For further information, please visit www.quantumpharmagroup.com.